StockData
Sunshine Biopharma Inc. logo

Sunshine Biopharma Inc. (SBFMW) stock

SBFMWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SBFM
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 10/30
$0.03+0.00 (+2.00%)

Close on Oct 30, 2026Market cap $11.36MP/E –Yield –

Earnings

Sunshine Biopharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q3 FY2024
$8.44M
+41.6% on a year earlier
EPS, Q3 FY2024
–
-$0.04 a year earlier
Latest guidance
Issued
Nov 13, 2023 · 1 item

Quarterly results

Revenue and earnings per share from each of Sunshine Biopharma's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q1 FY2026ended Mar 31, 2026Apr 9, 2026after the close–––Release
Q1 FY2025ended Mar 31, 2025Apr 2, 2025during market hours–––Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024after the close$8.44M+41.6%–Release
Q2 FY2024ended Jun 30, 2024Aug 19, 2024after the close$9.30M+67.3%–Release
Q1 FY2024ended Mar 31, 2024Apr 1, 2024during market hours–––Release
Q3 FY2023ended Sep 30, 2023Nov 13, 2023before the open$5.96M–-$0.04Release
Q2 FY2023ended Jun 30, 2023Aug 11, 2023before the open$5.56M––Release
Q1 FY2023ended Mar 31, 2023May 11, 2023after the close$4.89M––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Sunshine Biopharma's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
generic prescription drugsFY202467–NewNov 13, 2023

Guidance history

Every forecast Sunshine Biopharma put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 13, 2023generic prescription drugsFY202467New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Sunshine Biopharma filed with the SEC as exhibits to Form 8-K or 6-K

  1. On Thursday, October 08, 2026 at 8:00 AM ET
    News
  2. Inc. Announces Closing of up to $20.4 Million Public Offering
    News
  3. PRESS RELEASE, DATED MAY 18, 2026
    News
  4. PRESS RELEASE DATED MAY 19, 2026
    News
  5. Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
    Results
  6. ENGAGEMENT AGREEMENT BETWEEN THE COMPANY AND AEGIS
    News
  7. Sunshine Biopharma Reports 2025 First
    Results
  8. PRESS RELEASE, DATED APRIL 2, 2025
    News
  9. PRESS RELEASE, DATED APRIL 3, 2025
    News
  10. Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year
    Results
  11. SUNSHINE BIOPHARMA REPORTS 2024 THIRD QUARTER
    Results
  12. SUNSHINE BIOPHARMA REPORTS 2024 SECOND QUARTER
    Results
  13. SUNSHINE BIOPHARMA REPORTS 2024 FIRST QUARTER
    Results
  14. BIOPHARMA REPORTS OPERATING RESULTS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023
    Results
  15. PRESS RELEASE DATED FEBRUARY 13, 2024
    News